Abstract: SA-PO0660
Real-World Characteristics of Patients with IgAN Receiving Combination Therapy: A Retrospective Claims Analysis
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Trenz, Helen, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Ndife, Briana C., Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Haile-Meskale, Ruth, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Moradi, Hamid, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Erb, Raquel Skyla, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Prasad, Shiwani Kumari, Novartis Healthcare Private Limited, Mumbai, MH, India
- Bhattacharjee, Rashmi, Novartis Healthcare Private Limited, Mumbai, MH, India
- Helmuth, Margaret, University of Michigan, Ann Arbor, Michigan, United States
- Mariani, Laura H., University of Michigan, Ann Arbor, Michigan, United States
Background
The IgAN therapeutic landscape continues to evolve rapidly, with five targeted therapies approved since late 2021. The new KDIGO guideline emphasizes the importance of a multifaceted treatment approach to address the drivers of nephron loss and achieve disease management goals. This analysis describes patients (pts) initiating a combination of IgAN-specific therapies in the US.
Methods
This retrospective cohort study included adults (aged ≥18 years) who initiated ≥2 FDA-approved IgAN-specific therapies—targeted-release budesonide, sparsentan, iptacopan, and atrasentan—within 60 days of each other in the Komodo Healthcare Map™ database (Feb 1, 2023–Dec 4, 2025). The start date of the 2nd therapy was the index date. To ensure ≥30 days of treatment overlap, the 1st therapy required ≥90-day supply. Pts had ≥12 months’ pre-index continuous enrollment; other therapy indications were excluded. Outcomes included demographics, clinical characteristics, and pre-index treatment history, obtained from linked Diaceutics proprietary DXRX, Prognos Health, and Quest lab databases.
Results
The study identified 310 pts initiating ≥2 IgAN-specific therapies during the study period. The mean ± SD age was 45 ± 14.4 years, 39% were female, and 70% were commercially insured. Median (interquartile range [IQR]) pre-index urine protein-creatinine ratio (UPCR) was 1.5 (0.7–2.7) g/g; 60% of pts had positive hematuria pre-index. Median (IQR) pre-index eGFR was 48 (34–70) mL/min/1.73m2. Oxford MEST-C scoring of renal biopsies (mesangial hypercellularity [M], endocapillary hypercellularity [E], segmental glomerulosclerosis [S], interstitial fibrosis/tubular atrophy [T], and cellular crescents [C]) showed 58.5% of pts had M1, 30.2% had E1, 67.9% had S1, 34%/3.8% had T1/T2, and 39.6%/15.1% had C1/C2. The mean (median) time between the 1st and 2nd therapy initiation was 14 (9) days. In pre-index, RASi were used by 93.2% of pts, SGLT2i by 55.8%, and immunosuppressants by 76.5%.
Conclusion
This study provides real-world evidence on characteristics of pts receiving a combination of IgAN-specific therapies, demonstrating the increasing adoption of multi-mechanistic treatment strategies in clinical practice. These findings align with KDIGO guideline recommendations emphasizing simultaneous targeting of complementary disease pathways in IgAN.
Acknowledgment
Editorial and publication support were provided by Elizabeth Murray, PhD (BOLDSCIENCE Ltd., UK), and funded by Novartis Pharmaceuticals Corporation. This abstract was developed in accordance with Good Publication Practice (GPP) guidelines. The authors had full control of the content and made the final decision on all aspects of this publication.
Funding
- Commercial Support – Novartis Pharmaceuticals Corporation